Nateglinide
Nateglinide. Meglitinide — same K-ATP channel closure mechanism as repaglinide, faster onset. Pre-prandial dosing for post-prandial glucose.… Oral half-life 1.5 h.
Meglitinide — same K-ATP channel closure mechanism as repaglinide, faster onset. Pre-prandial dosing for post-prandial glucose. CYP2C9 + CYP3A4 substrate.
PK: PHYSICALLY SOUND, PROVENANCE THIN, AND ONE COINCIDENCE WORTH NOT ACTING ON. The cited paper states none of the four stored values but is useful for the arithmetic — "Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h" — against which this record 6.33 is 0.80 times the wild-type median, well within the spread. The bioavailability is now replaceable verbatim from a paper that was not cited: "The pharmacokinetics of nateglinide are characterised by rapid absorption and elimination, with good (73%) bioavailability", matching the stored value exactly. The volume is label-only, attributed by the label to intravenous data so the pairing is correct in principle, and the half-life sits inside published values without being any of them. THE ABSORPTION RATE IS PLAUSIBLE BUT SLOW AND UNSOURCED: it is this catalog shared default across fourteen records, it implies a 1.18 h peak against a real 0.5 to 1.0, and it is NOT a back-derivation. A COINCIDENCE IS FLAGGED AND DELIBERATELY NOT CALLED: nateglinide published elimination half-life is 1.4 HOURS verbatim, the same numeral as the stored absorption rate, which is exactly the half-life-as-rate collision shape — but thirteen other records share that same rate and the shared-default explanation covers all of them, so calling it here would be pattern-matching rather than evidence. Worth checking whether the other thirteen show similar coincidences.
Pharmacokinetics
- Oral — t½ 1.5 h · F 73% · Vd 10 L
Sources: PMID:15005635, PMID:14748619